Showing 6571-6580 of 9119 results for "".
- New Practice Offers Personalized Procedureshttps://practicaldermatology.com/news/20120926-new_practice_offers_personalized_procedures/2459730/Dermatologist Candace Thornton Spann, MD, FAAD, and plastic surgeon Marvin Spann, MD, established a joint practice, Couture Dermatology & Plastic Surgery. The practice, which opens October 1, will offer custom-tailored treatments for all et
- New Survey: Rosacea Inflicts Physical Discomforthttps://practicaldermatology.com/news/20120925-new_survey_rosacea_inflicts_physical_discomfort/2459731/A recent survey conducted by the National Rosacea Society (NRS) shows that significant physical discomfort often accompanies the visible signs of rosacea. In the survey of 1,709 patients with rosacea, nearly 93 percent said they had experienced physical discomfort as a result of the disorder. A burn
- Physicians Report Health IT Growing But Systems Laghttps://practicaldermatology.com/news/20120921-physicians_report_health_it_growing_but_systems_lag/2459732/A new Optum Institute/Harris Interactive national survey provides insights into US consumers' willingness to view their medical records and engage with care providers online. The survey was conducted online within the United States among 1,000 US physicians, 2,870 US adults, and 400 US hospital exec
- Provectus Pharmaceuticals to Present Data on PV-10https://practicaldermatology.com/news/20120918-provectus_pharmaceuticals_to_present_data_on_pv-10/2459733/Provectus Pharmaceuticals, Inc. announced that final efficacy data from its Phase II trial of PV-10 in patients with Stage III-IV melanoma will be presented, including response rate and time-to-event (progression free survival and overall survival),
- p53R2 Regulates Proliferation and Chemosensitivity in Melanomahttps://practicaldermatology.com/news/20120918-p53r2_regulates_proliferation_and_chemosensitivity_in_melanoma/2459734/Expression of p53R2 significantly correlates with the depth of invasion and the tumor stage in melanoma, new research shows. (J Dermatol Sci; 68(1):19-24) Furthermore, use of siRNA targeting p53R2 successfully knocked down p53R2 and significantly inhibited the growth of KHm5 and 6 cells. The degree
- NeoStrata Launches SKIN ACTIVE Perfecting Peelhttps://practicaldermatology.com/news/20120918-neostrata_launches_skin_active_perfecting_peel/2459736/NeoStrata Company, Inc., the creators of the original glycolic acid peel, introduced the Perfecting Peel to SKIN ACTIVE, its line of antiaging skincare. SKIN ACTIVE Perfecting Peel is formulated with a 20% alpha hydroxy acid blend of 10% citric
- Humira Talking Pen Launched to Educate on Self-injectionhttps://practicaldermatology.com/news/20120917-humira_talking_pen_launched_to_educate_on_self-injection/2459737/Abbott Laboratories, makers of Humira, released the Humira Talking Training Pen, available at no cost as part of the myHUMIRA patient support program (humira.com/m
- CMS Provider Call Today on EHRshttps://practicaldermatology.com/news/20120913-cms_provider_call_today_on_ehrs/2459740/The Centers for Medicare and Medicaid Services will host a 90-minute National Provider Call today, Sept. 13, to discuss the final rule for the Stage 2 electronic health records meaningful use program. The call is free, but prior registration is required.
- Direct-to-Consumer Pharmaceutical Advertising: Minimizing Risks?https://practicaldermatology.com/news/20120912-letter_to_editor_discusses_changes_in_direct-to-consumer_pharmaceutical_advertising/2459741/When prescription drugs switch to over-the-counter status, regulatory oversight of their advertising shifts to the Federal Trade Commission (FTC), potentially leading to reduced focus on warnings about risks and side effects, a new report suggests. While the FDA regulates prescription drug advertisi
- Valeant Acquires Medicis Pharmaceutical Corp. for $2.6 Billionhttps://practicaldermatology.com/news/20120904-valeant_acquires_medicis_pharmaceutical_for_26_billion/2459743/Valeant Pharmaceuticals announced an agreement to acquire Medicis Pharmaceutical for $44 per share in cash, in a deal worth approximately $2.6 billion. The transaction is expected to close in the first half of 2013 and has been approved by each company's board of directors. The combined operations w